Dark

ROG
Rogers Corporation
stock NYSE

At Close

Jul 30, 2026 3:59:55 PM EDT

122.05USD+4.549%(+5.31)230,232

95.26Bid 151.18Ask 55.92Spread

Pre-market

0.00USD-100.000%(-119.18)0

After-hours

Jul 29, 2026 4:10:30 PM EDT

116.79USD+0.043%(+0.05)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 28, 2022

06:45PM EST FDA Approves Genentech's Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss Business Wire

Jan 25, 2022

11:49AM EST Rogers' Shareholders Approve Acquisition By DuPont RTTNews

01:06AM EST Roche: FDA Grants Priority Review For Evrysdi For Treatment Of Pre-symptomatic Babies With Spinal Muscular Atrophy RTTNews

01:00AM EST Genentech's Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-Symptomatic Babies Under 2 Months of Age With Spinal Muscular Atrophy (SMA) Business Wire

Jan 24, 2022

10:22AM EST Lancet Publishes Studies Showing Genentech' Faricimab Improved & Maintained Vision In Two Leading Causes Of Vision Loss RTTNews

10:05AM EST The Lancet Publishes Studies Showing Genentech's Faricimab Improved and Maintained Vision in Two Leading Causes of Vision Loss, Extending Time Between Treatments up to Four Months Business Wire

Dec 17, 2021

01:04AM EST Roche Gets CE Mark For Use Of Saliva Samples With Cobas SARS-CoV-2 Qualitative Test On Cobas 6800/8800 Systems RTTNews

01:00AM EST Roche receives CE mark for the use of saliva samples with cobas SARS-CoV-2 PR Newswire

Dec 15, 2021

01:02AM EST Roche Launches Infectious Disease Tests And Cobas Omni Utility Channel For Use On Cobas 5800 System RTTNews

01:00AM EST Channel for use on the cobas 5800 System in countries accepting the CE Mark PR Newswire

Dec 14, 2021

10:22AM EST CJS Securities Downgrades Rogers to Market Perform, Announces $277 Price Target Benzinga

09:08AM EST Genentech' Polivy Combination Reduced Risk Of Disease Worsening/ Death By 27% In People With Aggressive Form Of Lymphoma RTTNews

09:00AM EST Genentech's Polivy Combination Reduced the Risk of Disease Worsening or Death by 27% in People With Previously Untreated Aggressive Form of Lymphoma Business Wire

Dec 13, 2021

01:05AM EST Genentech Says Interim Data From Phase III HAVEN 6 Study Demonstrate Favorable Safety And Efficacy Profile Of Hemlibra RTTNews

01:00AM EST Interim Data From Phase III HAVEN 6 Study Demonstrate Favorable Safety and Efficacy Profile of Genentech's Hemlibra (emicizumab-kxwh) in People With Moderate or Mild Hemophilia A Business Wire

Dec 11, 2021

08:56AM EST Genentech Presents Pivotal Data For Novel Cancer Immunotherapy Mosunetuzumab RTTNews

08:30AM EST Genentech Presents Pivotal Data at ASH 2021 for Novel Cancer Immunotherapy Mosunetuzumab Business Wire

Dec 10, 2021

03:05AM EST Genentech Announces Encouraging Results From Phase II CITYSCAPE Trial RTTNews

03:00AM EST New Data From the Phase II CITYSCAPE Trial Show Encouraging Results With Genentech's Novel Anti-TIGIT Tiragolumab Plus Tecentriq Business Wire

Dec 7, 2021

07:59AM EST Recursion Collaborates With Roche, Genentech In Neuroscience And Oncology RTTNews

07:55AM EST Neuroscience and Oncology, Advancing Novel Medicines to Patients Using Machine Learning and High Content Screening Methods at Scale to Map Complex Biology PR Newswire

01:02AM EST Roche Introduces Three AI-based, Deep Learning Image Analysis Research Use Only Algorithms Developed For Breast Cancer RTTNews

01:00AM EST pathology algorithms to aid pathologists in evaluation of breast cancer markers, Ki-67, ER and PR PR Newswire

Nov 23, 2021

09:15AM EST Genentech to Present New Pivotal Data at ASH 2021 From Broad and Comprehensive Portfolio, Challenging Treatment Standards for People With Blood Disorders Business Wire

Nov 20, 2021

12:32AM EST Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Rogers Corporation (NYSE:ROG) PR Newswire

Nov 4, 2021

10:20AM EDT Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2021 Benzinga

08:09AM EDT Stifel Downgrades Rogers to Hold, Raises Price Target to $277 Benzinga

05:34AM EDT Canaccord Genuity Downgrades Rogers to Hold, Raises Price Target to $277 Benzinga

Nov 3, 2021

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2021 Benzinga

09:14AM EDT Wolfe Research Downgrades Rogers to Peer Perform Benzinga

Nov 2, 2021

07:31PM EDT Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Rogers Corporation - ROG PR Newswire

02:32PM EDT Mid-Afternoon Market Update: Dow Rises Around 150 Points; Semler Scientific Shares Slide Benzinga

12:09PM EDT Mid-Day Market Update: Avis Budget Surges After Q3 Results; Chegg Shares Plunge Benzinga

10:53AM EDT DuPont To Acquire Rogers At 33% Premium Benzinga

10:45AM EDT Rogers Corporation Sees Q3 Adj. EPS $1.70-$1.85 vs $1.84 Est. Benzinga

10:45AM EDT Rogers Q3 Adj. EPS $1.64 Misses $1.78 Estimate, Sales $238.30M Miss $240.01M Estimate Benzinga

10:44AM EDT DuPont Announces Acquisition Of Rogers Corporation For ~$5.2B In Cash; Rogers' Shareholders To Receive $277/Share In Cash Benzinga

10:03AM EDT Shares of engineered materials and components maker Rogers Corporation (ROG) are surging more than 28% in the morning trade on Tuesday following the news of it being bought by DuPont (DD) for about $5.2 billion, to be paid in cash. RTTNews

07:02AM EDT Rogers Corp. (ROG), a provider of engineered materials and components, reported Tuesday higher profit in its third quarter with strong growth in sales. Adjusted earnings and top line, meanwhile, missed market estimates. RTTNews

06:43AM EDT Rogers Corp. Agrees To Be Acquired By DuPont In About $5.2 Bln Deal RTTNews

06:40AM EDT While reporting improved third-quarter results on Tuesday, chemical company DuPont De Nemours & Co. (DD) trimmed its forecast for fiscal 2021 earnings and sales, both below market estimates. RTTNews

06:33AM EDT Rogers Corporation Q3 EPS $1.33; Adj EPS $1.64 RTTNews

06:05AM EDT Rogers Corporation Reports Third Quarter 2021 Results Business Wire

06:01AM EDT DuPont Reports Third Quarter 2021 Results PR Newswire

06:01AM EDT DuPont Q3 GAAP EPS From Cont Opns $0.80; Adj EPS $1.15; Announces Strategic Actions RTTNews

06:00AM EDT DuPont Announces Acquisition of Rogers Corporation Business Wire

05:59AM EDT DuPont Announces Strategic Actions to Enhance Portfolio for Near and Long-term PR Newswire

Oct 28, 2021

01:03AM EDT Roche And Zur Rose Collaborate To Improve Everyday Therapy Management For People Living With Diabetes RTTNews

01:00AM EDT Roche and the Zur Rose Group announce collaboration to offer innovative health PR Newswire

Oct 22, 2021

02:30PM EDT FDA Approves Genentech's Susvimo, a First-of-Its-Kind Therapeutic Approach for Wet Age-Related Macular Degeneration (AMD) Business Wire

Oct 21, 2021

04:15PM EDT Rogers Schedules Q3 2021 Earnings Call for November 4, 2021 Business Wire

Oct 18, 2021

01:04AM EDT Roche Enters Deal With Ibex Medical Analytics To Develop Artificial Intelligence-based Digital Pathology Applications RTTNews

01:00AM EDT Roche announces collaboration with Ibex Medical Analytics to develop artificial PR Newswire

Oct 15, 2021

12:30PM EDT FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer Business Wire

Oct 14, 2021

01:06AM EDT Genentech Says Enspryng Significantly Reduces Debilitating Relapses In Neuromyelitis Optica Spectrum Disorder RTTNews

01:00AM EDT New 4-Year Data Show Genentech's Enspryng (satralizumab-mwge) Significantly Reduces Debilitating Relapses in People With Neuromyelitis Optica Spectrum Disorder Business Wire

Oct 13, 2021

01:06AM EDT Roche Announces New Long-term Data Of OCREVUS In On Disability Progression Relapsing Multiple Sclerosis And PPMS RTTNews

01:00AM EDT New Data up to 8-Years for Genentech's Ocrevus (ocrelizumab) Show Early and Ongoing Treatment Significantly Reduced Risk of Requiring a Walking Aid in Relapsing Multiple Sclerosis and Disability Progression in Primary Progressive Multiple Sclerosis Business Wire

Oct 8, 2021

04:57PM EDT Genentech's Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy Designation In Alzheimer's Disease RTTNews

11:40AM EDT Ad hoc announcement pursuant to Art. 53 LR: Genentech's Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy Designation in Alzheimer's Disease Business Wire

08:31AM EDT Rogers Acquires Silicone Engineering; Terms Undisclosed RTTNews

08:30AM EDT Rogers Announces Acquisition Of Silicone Engineering; Terms Not Disclosed Benzinga

08:27AM EDT Rogers Announces Acquisition of Silicone Engineering Business Wire

Oct 5, 2021

01:05AM EDT Genentech To Present New Data On Ocrevus In Multiple Sclerosis and Enspryng In Neuromyelitis Optica Spectrum Disorder RTTNews

01:00AM EDT Genentech to Present New Data on Ocrevus (ocrelizumab) in Multiple Sclerosis and Enspryng (satralizumab-mwge) in Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2021 Business Wire

Sep 20, 2021

09:16AM EDT Genentech : Phase III Data Support Benefit Of Tecentriq In Early-stage Lung Cancer RTTNews

09:05AM EDT New Phase III Data Support the Benefit of Genentech's Tecentriq in Early-stage Lung Cancer Business Wire

Sep 7, 2021

01:00AM EDT Genentech to Present Data From Industry-Leading Portfolio at ESMO 2021 Showing Significant Progress in Early Stage and Uncommon Cancers Business Wire

12:02AM EDT NeuExcell, Spark Therapeutics Announce Gene Therapy Collaboration For Huntington's Disease RTTNews

12:00AM EDT NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration PR Newswire

Aug 27, 2021

11:45AM EDT Genentech Provides Update on Tecentriq U.S. Indication for PD-L1-Positive, Metastatic Triple-Negative Breast Cancer Business Wire

Aug 9, 2021

01:06AM EDT Roche Says Phase III POLARIX Trial Meets Primary Endpoint RTTNews

01:00AM EDT Phase III Study Shows Genentech's Polivy Plus R-CHP Is the First Regimen in 20 Years to Significantly Improve Outcomes in Previously Untreated Aggressive Form of Lymphoma Compared to Standard of Care Business Wire

Aug 3, 2021

01:03AM EDT FDA Grants Priority Review To Genentech's Tecentriq As Adjuvant Treatment For Early Non-small Cell Lung Cancer RTTNews

01:00AM EDT FDA Grants Priority Review to Genentech's Tecentriq as Adjuvant Treatment for Certain People With Early Non-small Cell Lung Cancer Business Wire

Jul 30, 2021

09:59AM EDT Canaccord Genuity Maintains Buy on Rogers, Lowers Price Target to $233 Benzinga

Jul 29, 2021

04:57PM EDT Rogers Corporation Sees Q3 Adj. EPS $1.70-$1.85 vs $1.96 Est., Sales $235M-$245M vs $240.58M Est. Benzinga

04:57PM EDT Rogers Q2 Adj. EPS $1.72 Misses $1.88 Estimate, Sales $234.90M Miss $235.74M Estimate Benzinga

04:34PM EDT Rogers Corp. Q2 EPS $1.52 Vs. $0.78 Year Ago RTTNews

04:09PM EDT Rogers Corporation Reports Second Quarter 2021 Results Business Wire

04:23AM EDT Earnings Scheduled For July 29, 2021 Benzinga

02:00AM EDT FDA Accepts Application For Genentech's Faricimab For Wet Age-Related Macular Degeneration And Diabetic Macular Edema RTTNews

01:00AM EDT FDA Accepts Application for Genentech's Faricimab for the Treatment of Wet Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME) Business Wire

Jul 28, 2021

05:00PM EDT Data for Genentech's Evrysdi (risdiplam) Published in New England Journal of Medicine Shows Significant Improvement in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA) Business Wire

Jul 21, 2021

01:10AM EDT Roche: FDA Grants Breakthrough Therapy Designation For Venclexta With Azacitidine For Myelodysplastic Syndromes RTTNews

01:00AM EDT FDA Grants Breakthrough Therapy Designation for Venclexta in Combination With Azacitidine for the Treatment of Patients With Myelodysplastic Syndromes Business Wire

Jul 19, 2021

01:00AM EDT New Data for Genentech's Hemlibra (emicizumab-kxwh) Reinforce Safety Profile in People With Hemophilia A Business Wire

Jul 15, 2021

05:00PM EDT Rogers Schedules Q2 2021 Earnings Call for July 29, 2021 Business Wire

Jun 24, 2021

07:15PM EDT Genentech's Actemra Receives FDA Emergency Use Authorization for the Treatment of COVID-19 In Hospitalized Adults and Children Business Wire

01:06AM EDT Genentech: FDA Accepts Application For Port Delivery System With Ranibizumab For Wet Age-Related Macular Degeneration RTTNews

01:00AM EDT FDA Accepts Application for Genentech's Port Delivery System With Ranibizumab (PDS) for Treatment of Wet Age-Related Macular Degeneration (AMD) Business Wire

Jun 18, 2021

11:30AM EDT for PCR testing of both symptomatic and asymptomatic individuals at the point of care PR Newswire

Jun 11, 2021

01:06AM EDT Genentech To Present Latest Data From Three Pivotal Phase III Studies Of Venclexta RTTNews

01:03AM EDT Genentech Announces Data at EHA2021 Reinforcing Efficacy of Venclexta Combinations in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia Business Wire

01:00AM EDT New Genentech Data for Evrysdi (risdiplam) Show Improved Motor Function in Pre-Symptomatic Babies After One Year and Confirm Safety Profile in Previously Treated People With Spinal Muscular Atrophy (SMA) Business Wire

Jun 10, 2021

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2021 Benzinga

06:45AM EDT Wolfe Research Initiates Coverage On Rogers with Outperform Rating Benzinga

Jun 4, 2021

08:00AM EDT Genentech Presents Latest Advances With Immunotherapies in Non-Hodgkin's Lymphoma Business Wire

Jun 3, 2021

01:45PM EDT Rogers to Participate in Stifel's Cross Sector Conference Business Wire

May 26, 2021

10:09AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 26, 2021 Benzinga

08:14AM EDT Rogers Settles Patent Infringement Litigation Initiated Against KCC RTTNews

08:07AM EDT Rogers Announces Settlement Of Patent Infringement Lawsuits Against KCC Benzinga

07:33AM EDT Canaccord Genuity Initiates Coverage On Rogers with Buy Rating, Announces Price Target of $260 Benzinga

May 25, 2021

02:09PM EDT Fortify and Rogers Corporation Partner to Develop 3D Printed Dielectric PR Newswire

May 19, 2021

05:00PM EDT Pivotal Phase III Data at ASCO Show Genentech's Tecentriq Helps Certain People With Early Lung Cancer Live Significantly Longer Without Their Disease Returning Business Wire

May 18, 2021

01:00AM EDT Roche receives FDA authorisation for testing of asymptomatic people with the PR Newswire

May 11, 2021

01:00AM EDT Genentech to Present Data From One of the Most Comprehensive Oncology Portfolios at the 2021 ASCO Annual Meeting Showcasing Advancements for People Living With Cancer Business Wire

Apr 29, 2021

04:41PM EDT Recap: Rogers Q1 Earnings Benzinga

04:40PM EDT Rogers Corp Sees Q2 Adj. EPS $1.80-$1.95 vs $1.80 Est. Benzinga

04:40PM EDT Rogers Corp. Q1 EPS $1.66 Vs. $0.71 Year Ago RTTNews

04:39PM EDT Rogers Appoints Ram Mayampurath As CFO RTTNews

04:39PM EDT Rogers Q1 Adj. EPS $1.92 Beats $1.79 Estimate, Sales $229.26M Beat $220.00M Estimate Benzinga

04:27PM EDT Rogers Names Ram Mayampurath CFO Benzinga

04:09PM EDT Rogers Corporation Reports First Quarter 2021 Results Business Wire

04:05PM EDT Rogers Appoints Ram Mayampurath Chief Financial Officer Business Wire

04:10AM EDT Earnings Scheduled For April 29, 2021 Benzinga

Apr 28, 2021

04:17PM EDT FDA Advisory Committee Votes in Favor of Maintaining Accelerated Approval of Genentech's Tecentriq for Previously Untreated Metastatic Bladder Cancer Business Wire

11:03AM EDT Earnings Outlook for Rogers Benzinga

Apr 27, 2021

06:32PM EDT FDA Advisory Committee Votes in Favor of Maintaining Accelerated Approval of Genentech's Tecentriq for PD-L1-Positive, Metastatic Triple-Negative Breast Cancer Business Wire

Apr 22, 2021

09:57AM EDT B. Riley FBR Maintains Buy on Rogers, Raises Price Target to $240 Benzinga

Apr 16, 2021

01:11AM EDT Genentech Report New Data For Ocrevus Reinforce Significant Benefit On Slowing Disease Progression In RRMS And PPMS RTTNews

01:00AM EDT New Data for Genentech's Ocrevus (ocrelizumab) Reinforce Significant Benefit on Slowing Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis Business Wire

Apr 15, 2021

04:30PM EDT Rogers Schedules Q1 2021 Earnings Call for April 29, 2021 Business Wire

01:00AM EDT Genentech's Evrysdi Continues to Improve Motor Function and Survival in Babies With Type 1 Spinal Muscular Atrophy (SMA) Business Wire

Apr 12, 2021

01:20PM EDT FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications Business Wire

Apr 8, 2021

01:04AM EDT Genentech To Present New Data For Approved And Investigational Medicines For Treatment Of Neurological Disorders RTTNews

01:00AM EDT New Genentech Data at 2021 AAN Highlight Impact and Breadth of Expanding Neuroscience Portfolio Business Wire

Mar 22, 2021

04:00PM EDT Genentech Provides Update on Tominersen Program in Manifest Huntington's Disease Business Wire

02:05AM EDT Genentech Says Phase III IMpower010 Study Evaluating Tecentriq Met Primary Endpoint Of DFS At Interim Analysis RTTNews

02:00AM EDT Pivotal Phase III Study Shows Genentech's Tecentriq Helped People With Early Lung Cancer Live Longer Without Their Disease Returning Business Wire

Mar 16, 2021

02:06AM EDT Genentech Announces New Exploratory 2-year Longer-term Data From Part 2 Of SUNFISH Study RTTNews

02:00AM EDT New 2-Year Data Show Genentech's Evrysdi (risdiplam) Continues to Demonstrate Improvement or Maintenance of Motor Function in People Aged 2-25 With Type 2 or Type 3 Spinal Muscular Atrophy (SMA) Business Wire

Mar 11, 2021

01:05AM EST Genentech Says Phase III REMDACTA Study Did Not Meet Its Primary Endpoint RTTNews

01:00AM EST Genentech Provides Update on the Phase III REMDACTA Trial of Actemra Plus Veklury in Patients With Severe COVID-19 Pneumonia Business Wire

Mar 9, 2021

01:00AM EST Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung PR Newswire

Mar 8, 2021

01:05AM EST Genentech Voluntarily Withdraws U.S. Indication For Tecentriq In Prior-platinum Treated Metastatic Urothelial Carcinoma RTTNews

01:00AM EST Genentech Provides Update on Tecentriq U.S. Indication in Prior-Platinum Treated Metastatic Bladder Cancer Business Wire

Mar 4, 2021

05:42PM EST Genentech's Actemra Becomes the First Biologic Therapy Approved by the FDA for Slowing the Rate of Decline in Pulmonary Function in Adults With Systemic Sclerosis-Associated Interstitial Lung Disease, a Rare, Debilitating Condition Business Wire

Mar 1, 2021

03:00PM EST Rogers Releases Inaugural Environmental, Social and Governance Report Business Wire

Feb 24, 2021

05:06PM EST Genentech Says Results From Evrysdi Study In Infants With Type 1 SMA Published In New England Journal Of Medicine RTTNews

05:00PM EST Genentech Announces Results From Evrysdi (risdiplam) Study in Infants With Type 1 Spinal Muscular Atrophy (SMA) Published in New England Journal of Medicine Business Wire

Feb 18, 2021

05:01PM EST Recap: Rogers Q4 Earnings Benzinga

05:00PM EST Rogers Sees Q1 EPS $1.72-$1.87 Vs. $1.29 Est., Sales $215M-$225M Vs. $204.9M Est. Benzinga

04:34PM EST Rogers Q4 EPS $1.58 Beats $1.42 Estimate, Sales $210.70M Beat $203.53M Estimate Benzinga

04:33PM EST Rogers Corp Announces The Retirement Of Michael Ludwig Who Was The Co. CFO Benzinga

04:13PM EST Rogers Corp. Q4 EPS $0.81 Vs. Loss $1.55 Year Ago RTTNews

04:10PM EST Rogers SVP And CFO Michael Ludwig Intends To Retire From Company In 2021 RTTNews

04:09PM EST Rogers Corporation Reports Fourth Quarter and Full Year 2020 Results Business Wire

04:07PM EST Rogers Corporation Announces Retirement Of CFO Benzinga

04:07PM EST Rogers Corporation Announces Retirement of Chief Financial Officer Business Wire

04:28AM EST Earnings Scheduled For February 18, 2021 Benzinga

Feb 17, 2021

10:05AM EST Earnings Preview for Rogers Benzinga

Feb 12, 2021

01:07AM EST Genentech Announces Detailed Results From Four Phase III Studies Of Investigational Bispecific Antibody, Faricimab RTTNews

01:00AM EST New Phase III Data Show Genentech's Faricimab Is the First Investigational Injectable Eye Medicine to Extend Time Between Treatments up to Four Months in Two Leading Causes of Vision Loss, Potentially Reducing Treatment Burden for Patients Business Wire

Feb 11, 2021

10:01AM EST quantitative test to aid in the improvement of care for transplant patients PR Newswire

Feb 10, 2021

09:29AM EST Rogers Corp. (ROG) announced Wednesday that there was a fire at its UTIS manufacturing facility in Ansan, South Korea on February 9, 2021. The site was safely evacuated and there were no reported injuries. But there is extensive damage to the manufacturing site. The source of the fire is currently under investigation. RTTNews

09:28AM EST B. Riley FBR Maintains Buy on Rogers, Raises Price Target to $215 Benzinga

09:18AM EST Rogers Reports Fire At Its UTIS Manufacturing Facility In Ansan, S. Korea RTTNews

09:15AM EST Rogers Corporation Reports Fire in S. Korea Plant Business Wire

Feb 8, 2021

12:00PM EST Rapid Antigen Test, allowing healthcare professionals to make fast decisions at the point of care PR Newswire

Feb 4, 2021

04:30PM EST Rogers Schedules Q4 & Full Year 2020 Earnings Call for February 18, 2021 Business Wire

Jan 25, 2021

01:04AM EST Genentech Reports Positive Topline Results From Two Identically Designed Phase III Studies, TENAYA And LUCERNE RTTNews

01:00AM EST Genentech's Faricimab Meets Primary Endpoint in Two Global Phase III Studies and Shows Potential to Extend Time Between Treatments up to 16 Weeks for People With Neovascular Age-Related Macular Degeneration Business Wire

Jan 21, 2021

01:06AM EST FDA Grants Priority Review To Genentech's Esbriet For Unclassifiable Interstitial Lung Disease RTTNews

01:00AM EST FDA Grants Priority Review to Genentech's Esbriet (pirfenidone) for Unclassifiable Interstitial Lung Disease Business Wire

Jan 5, 2021

01:04AM EST Genentech Says Tiragolumab Granted FDA Breakthrough Therapy Designation In Combination With Tecentriq RTTNews

01:00AM EST Genentech's Novel Anti-TIGIT Tiragolumab Granted FDA Breakthrough Therapy Designation in Combination With Tecentriq for PD-L1-High Non-Small Cell Lung Cancer Business Wire

Dec 21, 2020

01:05AM EST Genentech Says Positive Topline Results From Phase III Studies, YOSEMITE And RHINE, Evaluating Faricimab For DME RTTNews

01:00AM EST Genentech's Faricimab Meets Primary Endpoint and Shows Strong Durability Across Two Global Phase III Studies for Diabetic Macular Edema, a Leading Cause of Blindness Business Wire

Dec 14, 2020

03:15PM EST FDA Approves Genentech's Ocrevus (ocrelizumab) Shorter 2-Hour Infusion for Relapsing and Primary Progressive Multiple Sclerosis Business Wire

Dec 5, 2020

12:45PM EST Genentech Announces New Data Reinforcing the Long-Term Benefit of Venclexta-Based Combination for People With Relapsed or Refractory Chronic Lymphocytic Leukemia Business Wire

Dec 3, 2020

12:17PM EST Rogers Corp. Appoints Megan Faust And Keith Larson To Its Board Of Directors RTTNews

12:00PM EST Rogers Corporation Appoints Megan Faust and Keith Larson to its Board of Directors Business Wire

Dec 1, 2020

03:15PM EST Genentech Announces FDA Approval of Gavreto (pralsetinib) for People With Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancers Business Wire

11:34AM EST Genentech Announces FDA Approval of Xolair (omalizumab) for Adults with Nasal Polyps Business Wire

11:31AM EST Roche receives FDA Emergency Use Authorization for new semi-quantitative test PR Newswire

Nov 23, 2020

02:46PM EST Genentech Announces FDA Approval of Xofluza for the Prevention of Influenza Following Contact With an Infected Person Business Wire

06:17AM EST OneOncology And Genentech Announce First Clinical Trial Available To Patients Through OneR RTTNews

06:15AM EST OneOncology Partners with Genentech to Bring Personalized Cancer Research to PR Newswire

Nov 17, 2020

08:03AM EST Leading Diagnostics Companies Join Forces to Establish the Access to PR Newswire

Nov 5, 2020

09:06AM EST Genentech To Present New Data Across 16 Blood Disorders At American Society Of Hematology Annual Meeting RTTNews

09:00AM EST Genentech to Present New Data Across 16 Blood Disorders at the American Society of Hematology 2020 Annual Meeting Business Wire

Oct 30, 2020

03:15PM EDT Mid-Afternoon Market Update: Rogers Jumps Following Upbeat Q3 Results; Pitney Bowes Shares Plunge Benzinga

12:08PM EDT Mid-Day Market Update: Nasdaq Tumbles Over 300 Points; Acadia Healthcare Shares Gain After Q3 Results Benzinga

Oct 29, 2020

04:49PM EDT Rogers Corp. Q3 EPS $0.37 Vs. $1.25 Year Ago RTTNews

04:47PM EDT Recap: Rogers Q3 Earnings Benzinga

04:46PM EDT Rogers Sees Q4 EPS $1.30-$1.50 Vs. $1.02 Est., Sales $195M-$210M Vs. $186.93M Benzinga

04:45PM EDT Rogers Q3 EPS $1.45 Beats $1.00 Estimate, Sales $201.94M Beat $184.23M Estimate Benzinga

04:09PM EDT Rogers Corporation Reports Third Quarter 2020 Results Business Wire

12:45PM EDT companion diagnostic test for expanded EGFR TKI therapies in patients with non-small cell lung cancer PR Newswire

04:08AM EDT Earnings Scheduled For October 29, 2020 Benzinga

Oct 20, 2020

03:39PM EDT Rogers Schedules Q3 2020 Earnings Call for October 29, 2020 Business Wire

Oct 16, 2020

07:30PM EDT Genentech Announces Full FDA Approval for Venclexta Combinations for Acute Myeloid Leukemia Business Wire

Sep 28, 2020

01:05AM EDT Genentech Reports New 2-year Data From Part 1 Of Pivotal FIREFISH Study Of Evrysdi RTTNews

01:00AM EDT Genentech Presents New 2-Year Data for Evrysdi (risdiplam) in Infants With Type 1 Spinal Muscular Atrophy (SMA) Business Wire

Sep 19, 2020

10:20AM EDT Genentech Presents New Data From Multiple Phase III Studies of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020 Business Wire

Sep 18, 2020

01:04AM EDT Genentech Says Phase III EMPACTA Study Meets Primary Endpoint RTTNews

01:00AM EDT Genentech's Phase III EMPACTA Study Showed Actemra Reduced the Likelihood of Needing Mechanical Ventilation in Hospitalized Patients With COVID-19 Associated Pneumonia Business Wire

Sep 11, 2020

01:05AM EDT Genentech Announces New Data Of Ocrevus For People With Multiple Sclerosis RTTNews

01:00AM EDT New Data Further Reinforce Genentech's Ocrevus (ocrelizumab) as a Highly Effective Treatment for People With Multiple Sclerosis Business Wire

Sep 10, 2020

01:00AM EDT New Data Show Genentech's Enspryng Significantly Reduces Severity and Risk of Relapse in Neuromyelitis Optica Spectrum Disorder Business Wire

Sep 9, 2020

01:05AM EDT Genentech Expands Multiple Sclerosis Portfolio With Investigational BTK Inhibitor Fenebrutinib RTTNews

01:00AM EDT Genentech Expands Its Multiple Sclerosis Portfolio With Investigational BTK Inhibitor Fenebrutinib and Initiates Novel Clinical Trials for Ocrevus (ocrelizumab) Business Wire

Sep 4, 2020

07:00PM EDT Genentech Announces FDA Approval of Gavreto (pralsetinib) for the Treatment of Adults With Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer Business Wire

Sep 3, 2020

01:04AM EDT Genentech To Present New Multiple Sclerosis And Neuromyelitis Optica Spectrum Disorder Data At MSVirtual2020 RTTNews

01:00AM EDT Genentech to Present New Data in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder at MSVirtual2020 Business Wire

Aug 19, 2020

01:00AM EDT Genentech and Regeneron Collaborate to Significantly Increase Global Supply of REGN-COV2 Investigational Antibody Combination for COVID-19 Business Wire

Aug 15, 2020

02:41AM EDT ADDING MULTIMEDIA FDA Approves Genentech's Enspryng for Neuromyelitis Optica Spectrum Disorder Business Wire

Aug 14, 2020

10:30PM EDT FDA Approves Genentech's Enspryng for Neuromyelitis Optica Spectrum Disorder Business Wire

Aug 13, 2020

01:19AM EDT Genentech: FDA Accepts Application For Xolair Prefilled Syringe For Self-Administration Across All Indications RTTNews

01:07AM EDT FDA Accepts Application for Xolair (omalizumab) Prefilled Syringe for Self-Administration Across All Indications Business Wire

Aug 10, 2020

01:03AM EDT Genentech Reports Mixed Results Seen In Studies Evaluating Etrolizumab As An Induction Therapy RTTNews

01:00AM EDT Genentech Provides Update on Phase III Studies of Etrolizumab in People With Moderately to Severely Active Ulcerative Colitis Business Wire

Aug 7, 2020

07:03PM EDT ADDING MULTIMEDIA FDA Approves Genentech's Evrysdi (risdiplam) for Treatment of Spinal Muscular Atrophy (SMA) in Adults and Children 2 Months and Older Business Wire

01:45PM EDT FDA Approves Genentech's Evrysdi (risdiplam) for Treatment of Spinal Muscular Atrophy (SMA) in Adults and Children 2 Months and Older Business Wire

Aug 6, 2020

04:07PM EDT Genentech: Phase III IMpassion131 Study Did Not Meet Statistical Significance On Its Primary Endpoint RTTNews

04:00PM EDT Genentech Provides Update on Phase III Study of Tecentriq in Combination With Paclitaxel for People With Metastatic Triple-Negative Breast Cancer Business Wire

Aug 5, 2020

10:54AM EDT Rogers Corporation Introduces Griswold GripON(tm), an Advanced Line of PR Newswire

Jul 30, 2020

04:55PM EDT Rogers Sees Q3 Adj. EPS $0.90-$1.10 vs $1.05 Estimate, Sales $175M-$190M vs $202M Est. Benzinga

04:54PM EDT Rogers Q2 Adj. EPS $1.13 Beats $0.90 Estimate, Sales $191.20M Miss $197.10M Estimate Benzinga

04:46PM EDT Rogers Q2 EPS $0.78 Vs. $1.30 Year Ago RTTNews

04:35PM EDT FDA Approves Genentech's Tecentriq plus Cotellic and Zelboraf for People With Advanced Melanoma Business Wire

04:09PM EDT Rogers Corporation Reports Second Quarter 2020 Results Business Wire

04:06AM EDT Earnings Scheduled For July 30, 2020 Benzinga

01:05AM EDT designed to automate all common manual steps in molecular diagnostics laboratories PR Newswire

Jul 29, 2020

01:15AM EDT Genentech Says Phase III COVACTA Study Of Actemra Did Not Meet Its Primary Endpoint RTTNews

01:00AM EDT Genentech Provides an Update on the Phase III COVACTA Trial of Actemra in Hospitalized Patients With Severe COVID-19 Associated Pneumonia Business Wire

Jul 23, 2020

12:07PM EDT B. Riley FBR Maintains Buy on Rogers, Raises Price Target to $160 Benzinga

Jul 22, 2020

12:00PM EDT Phase III Data Show Port Delivery System With Ranibizumab Enabled Over 98% of Patients to Go Six Months Between Treatments for Neovascular Age-Related Macular Degeneration Business Wire

Jul 20, 2020

12:08PM EDT Rogers Schedules Q2 2020 Earnings Call for July 30, 2020 Business Wire

Jul 13, 2020

07:04AM EDT Roche, Summit Cancer Centers To Patner On Use Of New Digital Healthcare Tools To Enable Cancer Care RTTNews

07:00AM EDT Roche, Summit Cancer Centers to collaborate on use of new digital healthcare PR Newswire

01:07AM EDT Genentech Announces Results From Second Interim Analysis Of Phase IIIb STASEY Study RTTNews

01:06AM EDT Genentech Says Phase III IMagyn050 Study Did Not Meet Primary Endpoint Of Progression-free Survival RTTNews

01:03AM EDT New Data From Phase IIIb Study Reinforces Safety Profile of Genentech's Hemlibra (emicizumab-kxwh) in People With Hemophilia A Business Wire

01:00AM EDT Genentech Provides Update on Phase III Study of Tecentriq in Women With Advanced-stage Ovarian Cancer Business Wire

document.getElementById("jNvQRn").onerror = function(){this.style.display='none';}; .dark-mode .sxgqfR{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .sxgqfR{ color: #333333; background-color: white; border: 2px solid #333333; }ROGRogers Corporationstock NYSE

ROG
Rogers Corporation
stock NYSE